The results of a research study published in The New England Journal of Medicine declared that one of the most inexpensive and mature drugs might just be very effective against colon cancer. The normal routine and advanced cancer therapies target treatments for patients involving specific gene mutations, costing huge sum of money, but it’s not the case of this drug.
The use and effect of aspirin was studied with survival rate of colon cancer patients with tumors having mutations in the PIK3CA gene. The study claims that roughly every patient who took aspirin regularly with said mutation was still living after five years of diagnosis. These statistics were interrelated with only 3 out of 4 patients of the mutation who did not take aspirin regularly. A fraction of roughly 15% to 20% of colorectal cancer patients actually has this specific kind of mutation tumors.
The study concluded that aspirin has actually extended the lives of numerous patients dramatically, and this realization has led to new hopes regarding aspirin’s application in treatment of other patients. A researcher Shuji Ogino, MD, PhD, of Boston’s Dana-Farber Cancer Institute, identified that “aspirin appears to work to increase survival of colorectal cancer patients if the tumor has the PIK3CA mutation, but it does not work if the tumor does not have the mutation.”
So far aspirin was generally subscribed to patients with colorectal cancer, however the doctors were not certain if the patients did benefit from it or not. This research sampled a total of 964 patients categorized in the different studies of patients with colorectal cancer.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.